Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:06 PM
Ignite Modification Date:
2025-12-24 @ 9:06 PM
NCT ID:
NCT02357004
Eligibility Criteria:
Inclusion Criteria:
* Uncontrolled clinic BP (\>140/90 mmHg)
* Receiving 5 or more antihypertensive agents including an ACE inhibitor or ARB, calcium channel blocker, and chlorthalidone 25 mg
Exclusion Criteria:
* Current use of an alpha or beta or combined alpha-beta antagonist
* Known allergy to alpha-beta antagonists
* CKD (eGFR \<40 ml/min/m2)
* MI, stroke or episode of CHF exacerbation within 3 months
* Bradycardia \<50 bpm; history of 2nd or 3rd degree heart block unless treated by a pacemaker
* Pregnant or breast-feeding women
* Known hypersensitivity to chlorthalidone or other sulfonamide-derived drugs
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
19 Years
Maximum Age:
70 Years
Study:
NCT02357004
Study Brief:
Protocol Section:
NCT02357004